• Xenetic Biosciences highlighted positive preclinical data on DNase I as an add-on to CAR-T therapy at ASCO 2026 on June 1.
• Results were presented as a poster on June 1, 2026, with findings positioned to support continued clinical development.
• Studies showed DNase I improved CAR-T cell durability, limited functional decline, strengthened tumor control, and extended survival versus CAR-T alone.
• Translational observations in a pediatric refractory Burkitt lymphoma case linked DNase I co-administration to renewed CAR-T expansion and tumor reduction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.